Implantable Cardiac Pulse Generators: Pacemakers and Cardioverter-Defibrillators









  • Identify the type of cardiovascular implantable electronic device (CIED) (pacemaker, transvenous defibrillator, subcutaneous defibrillator), as well as the generator manufacturer and model of the CIED.



  • Contact the physician or clinic managing the patient’s CIED in the preoperative period to obtain appropriate records and a perioperative recommendation (Heart Rhythm Society [HRS]).



  • Obtain a copy of this interrogation and the perioperative recommendation from the CIED physician (HRS). Ensure that the implantable cardioverter-defibrillator (ICD) treatment settings are appropriate and that the CIED will pace the heart.



  • Consider replacing any CIED near its elective replacement period in a patient scheduled to undergo either a major surgical procedure or a surgical procedure where monopolar electrosurgery will be used within 15 cm of the generator.



  • Determine the patient’s underlying rate and rhythm to determine the need for backup (external) pacing support.



  • Ensure that all magnet behavior (pacing, suspension of shock therapy) is appropriate if magnet use is planned.



  • Program minute ventilation rate responsiveness “off,” if present.



  • Consider disabling all rate enhancements to prevent misinterpretation of cardiac rhythm.



  • Consider increasing the lower rate limit to provide optimal oxygen delivery for major procedures.



  • If electromagnetic interference is likely, (1) disable antitachycardia therapy if a defibrillator is present and (2) consider asynchronous pacing for some pacing-dependent patients. Magnet application may be acceptable for some ICDs (disable antitachycardia therapy) or pacemakers (provide asynchronous pacing). Asynchronous pacing from an ICD always requires reprogramming.



  • Monitor cardiac rhythm with the pulse oximeter (plethysmography) or arterial waveform analysis.



  • Use a bipolar electrosurgical unit (ESU), if possible; if not possible, then pure “cut” electrosurgery is better than “blend” or “coag,” and ESU should be applied in short bursts (<4 seconds) separated by at least 2 seconds.



  • Place the ESU dispersive electrode in such a way to prevent electricity from crossing the generator-heart circuit.



  • If the ESU causes ventricular oversensing with pacing quiescence or atrial oversensing with inappropriate ventricular pacing, limit the effect by using short ESU bursts, relocating the dispersive electrode, or placing a magnet over the pacemaker (not indicated for ICDs).



  • Some patients require postoperative interrogation, especially if preoperative reprogramming took place. For “low-risk cases,” HRS (but not ASA) states that this interrogation can take place in an ambulatory setting up to 1 month postoperatively. Some rate enhancements can be reinitiated, and a determination of optimum heart rate and pacing parameters should be made. Any patient with disabled antitachycardia therapy must be monitored until the antitachycardia therapy is restored.





Acknowledgment


The editors and publisher would like to recognize Dr. Marc A. Rozner for contributing a chapter on this topic in the prior edition of this work. It has served as the foundation for the current chapter.




Introduction


Cardiac implantable electronic devices (CIEDs) refer to a permanently implanted cardiac pacemaker, an implantable cardioverter-defibrillator (ICD), or a cardiac resynchronization therapy (CRT) device. Evolving technology for CIEDs and their widespread use for bradyarrhythmias, tachyarrhythmias, and congestive heart failure management have made the perioperative management of these devices critical for anesthesiologists. It is estimated that more than 3 million people in the United States have a pacemaker and more than 300,000 people have an ICD. With approximately 1 million patients worldwide receiving a pacemaker or ICD every year, patients with CIEDs are a growing population in the perioperative arena. The prevalence of cardiovascular disease in an aging population is an important driver for the increased utilization of CIEDs.


a Adapted from the American Society of Anesthesiologists (ASA) Practice Advisory (2005, revised 2011) and the Heart Rhythm Society (HRS), formerly the North American Society of Pacing and Electrophysiology (NASPE) and ASA Consensus Statement (2011) for Perioperative Management of Patients With a Pacemaker or Defibrillator.



Historically, there was little guidance for anesthesiologists caring for patients with CIEDs because of the conflicting consensus statements regarding the perioperative management of CIEDs. In 2011, the Heart Rhythm Society (HRS)/American Society of Anesthesiologists (ASA) published an Expert Consensus Statement on the perioperative management of patients with CIEDs. This statement was in collaboration with the American Heart Association (AHA) and the Society of Thoracic Surgeons (STS). This article provides information and a guided team approach to best manage this patient population, and it has become an important piece of literature for anesthesiologists. In this chapter, we will review basic CIED function, the perioperative management of these devices, and emerging technology of CIEDs.




Basic Cardiac Implantable Electronic Device Function


Pacemakers


Pacemakers are devices placed for bradyarrhythmias, and they remain the only effective treatment for ameliorating symptomatic bradycardia due to sinus node dysfunction (e.g., sick sinus syndrome) or a failure of impulse propagation (e.g., complete heart block). Advances in technology and understanding of cardiac conduction physiology have led to the development of more physiologic pacing. Pacemakers have become sophisticated at maintaining the normal atrial-ventricular activation over various heart rate ranges, varying the heart rate in response to metabolic demands, and preserving natural ventricular activation. Pacemakers have many additional features that correspond to the changing needs of patients throughout the day, including rate responsiveness to increase pacing during times of increased physical exertion and sleep functions to decrease pacing rate during times of rest. Standard pacemakers have either one or two (atrial and ventricular) leads. A patient is considered to be pacemaker dependent if they suffer significant symptoms or even cardiac arrest upon the cessation of pacing.


The dual chamber pacemakers are capable of pacing and sensing in both the ventricle and the atrium. Such capability permits the pacemaker to ensure not only an adequate ventricular rate, but to preserve the atrial contraction before each ventricular contraction. These pacemakers guarantee a minimum atrial rate and also ensure that a ventricular contraction occurs within a specified amount of time after each atrial contraction. Limitations on ventricular rate are usually built in the circuitry and are programmable. Most pacemakers have the capability of varying the pacing rate. In the rate adaptive mode, the pacemakers sense the patient’s level of activity and accordingly adjust the pacing rate using sensors that are typically piezoelectric and detect body motion transmitted from underlying muscles. Another method of determining the presence of physical activity utilizes detection of the respiratory rate and/or volume using bioimpedance sensors.


All pacemakers generate a pulse of current to depolarize a small region of the myocardium; the wave then spontaneously spreads to the rest of the myocardium. The pacing capture threshold is the minimum electrical energy needed to consistently capture the heart outside of the refractory period and is determined by (1) the intrinsic excitability of the myocardium, (2) the current density at the electrode-tissue interface, and (3) the duration of the electric pulse.


The North American Society of Pacing and Electrophysiology (NASPE) and the British Pacing and Electrophysiology Group (BPEG) initially published a generic pacemaker code (NBG code) in 1987. In 2002 the NBG code was subsequently revised ( Table 38.1 ). Common perioperative pacing modes include dual chamber, adaptive-rate pacing (DDDR), dual chamber pacing without atrium synchronous ventricular pacing (DDIR), and dual chamber asynchronous pacing with no rate modulation or multisite pacing (DOO).



  • 1.

    DDDR pacing defines a pacemaker programmed to pace the atrium and/or ventricle, sense the atrium and/or ventricle, inhibit or trigger pacing output in response to a sensed event, and have a rate responsive sensor that is able to alter paced rates due to changes in perceived metabolic demand. DDDR is a very common program configuration for patients with sick sinus syndrome and/or heart block.


  • 2.

    DDIR is a common pacing mode for patients with supraventricular tachyarrhythmias (SVTs). If a patient is set to DDD, the ventricle response depends on the atrial rate. During SVT in DDD mode, rapid ventricular pacing may occur. In DDI, the pacemaker paces and senses both the atrium and ventricle; however, the device will not pace the ventricle at an identical rate if the patient has SVT. The response to a fast rate in the atrium will lead to inhibition of pacing in the ventricle—hence the I in the third designation. Most modern pacemakers have built-in automatic mode switching during episodes of SVT. They will switch from DDD to DDI to avoid SVT with a rapid ventricular response.


  • 3.

    For some perioperative care, devices will be placed in an asynchronous mode like DOO. An asynchronous mode or nontracking mode will pace the atrium and ventricle at a set rate, regardless of the underlying rate and rhythm. This is advantageous in the perioperative environment in order to avoid the pacemaker from oversensing the monopolar electrocautery as intrinsic cardiac conduction. Asynchronous modes avoid oversensing (and under pacing) hearts that are pacemaker dependent and inhibited from pacing due to monopolar electrocautery ( Table 38.2 ).



    Table 38.2

    Common Pacemaker Settings












































    Examples Chamber Paced Chamber Sensed Response to Sensing Rate Modulation Multisite Pacing Common Clinical Utilization
    AAI Atrium Atrium Intrinsic atrial beat inhibits atrial pacing None None Sick sinus syndrome with intact atrioventricular conduction
    DDDR Both Both Intrinsic beat will inhibit output; atrial beat will trigger ventricular pacing if lack of intrinsic ventricular beat Present None Atrioventricular block
    VVIRV Ventricle Ventricle Intrinsic ventricular beat will inhibit ventricular pacing Present Multisite ventricular pacing Heart failure with prolonged QRS
    DOO Both None None None None Perioperative asynchronous setting to avoid electromagnetic interference



Table 38.1

2002 NASPE/BPEG Generic Code for Antibradycardic Pacing
























Position I II III IV V
Description Chamber Paced Chamber Sensed Response to Sensing Rate Modulation Multisite Pacing
Possible designations D = Dual (A+V)
A = Atrium
V = Ventricle
O = None
D = Dual (A+V)
A = Atrium
V = Ventricle
O = None
D = Dual (T+I)
T = Triggered
I = Inhibited
O = None
R = rate modulation
O = None
D = Dual (A+V)
A = Atrium
V = Ventricle
O = None


Implantable Cardioverter-Defibrillators


ICDs are implanted in patients for primary or secondary prevention of cardiac arrest. Primary prevention refers to ICD placement for patients who have not had any episodes of ventricular arrhythmias but who are at risk for future events. Secondary prevention refers to ICD placement for patients who have had prior ventricular arrhythmias. There is strong evidence that ICDs implanted for primary prevention improve mortality in high-risk patients, including patients with a left ventricular ejection fraction less than 40% who are on optimal medical therapy. For patients with ischemic and nonischemic cardiomyopathy, ICDs reduce mortality approximately 23% to 55%. Certain groups of patients do not benefit from ICD implantation, including patients with recent myocardial infarction and patients who have received coronary artery bypass grafting. In addition, many of the patients in the decisive trials for ICD placement were younger (mean or median age between 58 and 67 years for the MADIT-II, CABG-PATCH, DINAMIT), whereas many patients currently receiving ICDs are over the age of 70.


ICDs have four main functions. They sense atrial or ventricular electrical activity, classify these signals to various programmed “heart rate zones,” deliver tiered therapies to terminate ventricular tachycardia (VT) or fibrillation, and pace for bradycardia. All modern ICDs are pacemakers, and this has important perioperative applications. Although ICDs improve survival in many patients, unnecessary shocks are very detrimental. They are proarrhythmic, can lead to anxiety and depression, and decrease patient quality of life. Inappropriate shocks are common (30% to 50% of all shocks) as a result of inappropriate treatment of SVT, oversensing physiologic T waves, or lead fracture. The discrimination between VT and SVT is critical for ICDs to avoid inappropriate therapy. There are several methods by which ICDs discriminate between SVT and VT. Single chamber ventricular ICDs utilize ventricular–ventricular timing intervals and QRS morphology. Dual chamber ICDs use atrial–atrial timing intervals and the chamber of onset. Subcutaneous ICDs assess surface electrocardiogram (ECG). The sensitivity and specificity for VT detection by QRS morphology is more than 90%.


ICDs terminate ventricular arrhythmias by either antitachycardiac pacing (ATP) or defibrillation. ATP terminates reentrant VT by blocking reentry and it terminates slow VT (<188 to 200) approximately 90% of the time. ATP is desirable because it reduces inappropriate shocks and prolongs battery life. For VT that is not terminated by ATP or for ventricular fibrillation (VF), defibrillation is the treatment of choice. The energy for defibrillation may be incrementally increased or set to maximum energy for each shock.


Cardiac Resynchronization Therapy Devices


CRT plays an important role in the management of heart failure and is becoming a device commonly encountered by anesthesiologists because of the large prevalence of heart failure in this country. These devices are indicated in select patients with heart failure, systolic dysfunction, and a prolonged QRS. Conduction abnormalities are frequently seen in systolic heart failure, with approximately 25% to 40% of these patients having a prolonged QRS complex (>120 ms). In these patients, cardiac depolarization spreads slowly through the myocardium without a healthy Purkinje conduction system, leading to intraventricular dyssynchrony. During intraventricular dyssynchrony, the left ventricular (LV) septal wall contracts earlier than the lateral wall, which leads to less efficient ejection from the left ventricle in addition to decreased diastolic filling. The goal of CRT is to restore synchronous contraction of the left ventricle and to optimize timing of LV and right ventricular (RV) ejection. This is accomplished through biventricular pacing using a standard RV lead and an LV lead placed adjacent to the lateral wall via the coronary sinus. Biventricular pacing in the right ventricle and the left ventricle leads to improved hemodynamic variables, including systolic blood pressure, stroke volume, cardiac output, and rate of rise of LV pressure (d P /d t ). In contrast to pharmacologic means of improving systolic function, CRT improves cardiac performance with reductions rather than with increases in myocardial metabolic demand. In addition, CRT has been shown to improve mitral regurgitation (MR) and New York Heart Association (NYHA) function class because of reverse ventricular remodeling over time. Standard indications for CRT are LV ejection fraction (LVEF) less than 35% with QRS greater than 120 ms, sinus rhythm, and NYHA class III or IV after optimal medical therapy. Left bundle branch block is the most common conduction abnormality in patients undergoing CRT. Approximately 30% of patients meeting selection criteria for CRT do not respond to biventricular pacing. Risk factors for failure to respond to CRT include ischemic cardiomyopathy, sustained VT, severe MR, and dilated LV cavity. CRT has been shown to reduce mortality, heart failure symptoms, and also heart failure hospitalizations. Patients with CRT should be considered pacemaker-dependent because of the constant pacing they undergo to synchronize the ventricle.




Perioperative Considerations


Preoperative Assessment


As perioperative physicians, the preoperative assessment of patients with CIEDs is critical to safe and time-efficient care. The key to the preoperative assessment is timely communication between the anesthesia provider and the CIED team that usually manages the device programming and function. The CIED team may include a cardiologist, an electrophysiologist, and/or a physician extender such as a nurse or nurse practitioner. The CIED team needs to know various information about the surgical case and postoperative disposition in order to create an individualized care plan for the patient. The anesthesiology provider must communicate the specifics of perioperative care to the CIED team in order to ensure a proper plan specific to that patient and the surgical case. Unfortunately, there is no single prescription for CIED management that can be applied to all patients coming for surgery. In addition, it is not recommended that an industry-employed allied profession determine the perioperative plan for a particular CIED.


The perioperative team must convey to the CIED team important information regarding the presence of electromagnetic interference (EMI), the likelihood of cardioversion or defibrillation, patient position, location of surgery that may damage or encroach upon the CIED leads, and postoperative disposition. The CIED team must communicate with the anesthesiology team the date of last interrogation, the type of CIED device, the indication for CIED placement, the battery life, pacemaker dependence, and magnet response. Each of these vital perioperative parameters are discussed in detail in this chapter.


The goal of a thorough preoperative evaluation between the CIED and anesthesia teams is to avoid CIED complications in the perioperative period, such as damage to the device, inability of the device to deliver pacing or shocks, lead-tissue interface damage, changes in pacing behavior, electrical reset to the backup pacing mode, or inappropriate ICD therapies. Any of the these complications can lead to poor patient outcomes, including hypotension, arrhythmias, and myocardial ischemia.


Preoperative Information Transfer


The ACCF/AHA/HRS 2011 guidelines emphasize that a team approach should be utilized when caring for patients with CIEDs. Patients coming for surgery with CIEDs do not need routine interrogations prior to surgery unless there has been a change in clinical presentation. For patients with a pacemaker, they should have an interrogation report within the last 12 months; patients with an ICD or CRT should have a report within the previous 6 months. The different time courses for interrogations between pacemakers and ICDs and CRT devices reflect the overall cardiovascular comorbidities of these respective patient populations. By definition, patients with ICDs and CRT devices have decreased systolic function and heart failure, and they are more likely to have clinical decompensation compared to patients with isolated pacemakers. Worsening cardiovascular function might negatively impact CIED performance. The preoperative evaluation begins with general considerations, such as establishing whether a patient has a CIED and defining the type of device. A focused history and physical, including rhythm strips and ECGs, can usually answer important basic questions about the patient’s CIED. After these are completed, it is important to define the type of the device to be used. If the patient has been seen by the CIED team, they will leave a detailed note.


Within the interrogation report, it is important to note the type of device. Patients with pacemakers have different clinical risk profiles compared with those with ICDs and CRTs. In addition, the goals of perioperative management for these devices are different. Most pacemakers encourage intrinsic cardiac conduction because this maintains atrial–ventricular synchrony, LV-RV synchrony, and septal LV–lateral LV synchrony. Although DDD pacing of both atrium and ventricle in a dual-chamber pacemaker maintains atrioventricular (AV) synchrony, it creates RV-LV dyssynchrony and LV-LV dyssynchrony because pacing begins in the right ventricle and crosses the septum before activating the LV lateral wall. Preserved synchrony optimizes stroke volume, which is desirable during the perioperative environment. Therefore, in the perioperative environment, it is advantageous to maintain intrinsic cardiac conduction as much as possible if the surgical procedure and use of EMI permits. In contrast, CRT devices attempt to ensure pacing 100% of the time in order to optimize stroke volume.


The manufacturer and model should be noted, along with the indication for placement of the CIED, in order to troubleshoot problems. Theoretically all patients with CIEDs should carry identification cards that identify the type of CIED, the manufacturer, the model, and date of implantation. In practice, many patients do not carry their CIED cards, and it is left to the anesthesia provider to identify these parameters. There are several methods for obtaining this information. Frequently an interrogation note from the CIED team will identify all these parameters. Occasionally, patients present for elective surgery without CIED team communication. In this subset of patients, there are several options. One option for identifying the type of device and manufacturer is the use of chest radiographs ( Fig. 38.1 ). Chest radiographs can identify pacemakers versus ICDs, due to the increased thickness of the shocking coil in ICDs. Chest radiographs can also identify CRT devices due to the lead in the coronary sinus. With some training, the manufacturer can also be identified via chest radiograph ( Fig. 38.2 ). In situations where the patient does not have his or her card, or there is no CIED note and there is no chest radiograph available or it cannot be interpreted, then contact with the CIED manufacturers can be initiated, since they all keep clinical records of their patients. Communicating directly with the manufacturer can disclose information about the type of CIED, date of implantation, and original settings. Unfortunately, current information about pacemaker dependence and battery life is not usually available by phone.




Fig. 38.1


Chest radiograph: the pulse generator is located in the left deltopectoral groove.

There are three leads visualized: a lead in the right atrium (RA) , a lead in the left ventricle (LV) via the coronary sinus, and a lead in the right ventricle (RV) . The RV lead has a thicker diameter toward the tip, indicating it is an implantable cardioverter-defibrillator lead.



Fig. 38.2


Chest radiograph of the cardiovascular implantable electronic device generator.

The letter designation on the generator allows the physician to identify this manufacturer as St. Jude Medical.


Battery longevity is important to consider as an anesthesia provider. Three months of battery duration is reasonable in the perioperative period. This time point is chosen because battery life depends on the amount of pacing and the number of shocks delivered for pacemakers and ICDs, respectively. The burden of pacing in the perioperative period may be very different than the patient’s normal requirements. Sinoatrial (SA) and AV nodal suppressing agents such as opioids, beta-blockers, and calcium channel blockers administered in the hospital may increase pacing requirements; therefore it is prudent to have several months of battery life remaining. In addition, there may be unexpected postoperative complications leading to the increased duration of hospitalization. If a patient is presenting for elective surgery with a diminished battery life, the generator should be replaced prior to the surgery.


It is important to establish if the patient is pacemaker-dependent, which is defined as the absence of a perfusing rhythm without pacing. In order to establish pacemaker dependence, a history and chart review may identify an episode of bradyarrhythmia leading to syncope. In addition, for patients with refractory SVT, they will occasionally have an AV nodal ablation. This is a therapeutic procedure that establishes complete heart block to eliminate rapid ventricular response to SVT. This patient population is pacemaker-dependent. Patients with CRT devices can be considered pacemaker-dependent even if they have a normal sinus rate and intact AV conduction due to the hemodynamic deterioration they suffer with dyssynchrony of the RV-LV and LV-LV. Pacemaker dependence can be established by the CIED team preoperatively. They can decrease the pacing rate in a stepwise fashion to search for intrinsic electrical activity. If no intrinsic rate is present around 40 to 45 beats/min or the patient develops symptoms, the patient may be considered pacemaker-dependent. Some patients who are not pacemaker-dependent may become pacemaker-dependent in the perioperative period due to SA and AV nodal blocking agents; therefore, it is important to be prepared to address this clinical scenario. If the patient is deemed to be pacemaker-dependent, a secondary method for pacing the patient should be considered in the event of a pacemaker failure. Alternative methods of pacing patients intraoperatively include transesophageal pacing, transcutaneous pacing, or transvenous pacing through a pacing pulmonary artery catheter or through a temporary transvenous pacing wire. Transesophageal pacing activates the left atrium, which is in close proximity to the esophagus, so this type of pacing depends on intact AV node conduction. It will not work for heart block. Transcutaneous pacing depends on correct pad position and high pacing outputs, which can be very uncomfortable in a nonsedated patient. Transvenous pacing and pacing pulmonary artery catheters can be time consuming, and they are not ideal choices for emergent pacing. Whatever method is chosen, it is important to have the necessary equipment and support organized and available prior to beginning the procedure. A summary of important information for the anesthesia team to identify is summarized in Table 38.3 .


Mar 7, 2020 | Posted by in ANESTHESIA | Comments Off on Implantable Cardiac Pulse Generators: Pacemakers and Cardioverter-Defibrillators

Full access? Get Clinical Tree

Get Clinical Tree app for offline access